Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Deferred Revenue: 2016-2022

Historic Current Deferred Revenue for Spyre Therapeutics (SYRE) over the last 4 years, with Dec 2022 value amounting to $2.7 million.

  • Spyre Therapeutics' Current Deferred Revenue rose 219.59% to $930,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $930,000, marking a year-over-year increase of 219.59%. This contributed to the annual value of $2.7 million for FY2022, which is 14.29% up from last year.
  • As of FY2022, Spyre Therapeutics' Current Deferred Revenue stood at $2.7 million, which was up 14.29% from $2.4 million recorded in FY2021.
  • Spyre Therapeutics' Current Deferred Revenue's 5-year high stood at $2.7 million during FY2022, with a 5-year trough of $2.4 million in FY2021.
  • Its 2-year average for Current Deferred Revenue is $2.5 million, with a median of $2.5 million in 2021.
  • Data for Spyre Therapeutics' Current Deferred Revenue shows a peak YoY rose of 14.29% (in 2022) over the last 5 years.
  • Yearly analysis of 2 years shows Spyre Therapeutics' Current Deferred Revenue stood at $2.4 million in 2021, then climbed by 14.29% to $2.7 million in 2022.